UY37936A - AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 - Google Patents

AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1

Info

Publication number
UY37936A
UY37936A UY0001037936A UY37936A UY37936A UY 37936 A UY37936 A UY 37936A UY 0001037936 A UY0001037936 A UY 0001037936A UY 37936 A UY37936 A UY 37936A UY 37936 A UY37936 A UY 37936A
Authority
UY
Uruguay
Prior art keywords
agents
expression
inhibit
compositions
asgr1
Prior art date
Application number
UY0001037936A
Other languages
English (en)
Inventor
Stacey Melquist
Tao Pei
Zhen Li
D Given Bruce
Rui Zhu
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of UY37936A publication Critical patent/UY37936A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente memoria da a conocer composiciones y métodos para la inhibición de la expresión génica del receptor de asialoglicoproteína 1 (ASGR1). Se dan a conocer agentes de interferencia de ARN (iARN), por ejemplo, agentes iARN de doble hebra, y conjugados agente iARN-ligando dirigido a la diana para inhibir la expresión de un gen ASGR1. También se dan a conocer composiciones farmacéuticas que comprenden uno o más agentes iARN ASGR1, opcionalmente con uno o más agentes terapéuticos adicionales.
UY0001037936A 2017-10-17 2018-10-17 AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 UY37936A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573206P 2017-10-17 2017-10-17
US201762608606P 2017-12-21 2017-12-21
US201862635277P 2018-02-26 2018-02-26

Publications (1)

Publication Number Publication Date
UY37936A true UY37936A (es) 2019-05-31

Family

ID=66173364

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037936A UY37936A (es) 2017-10-17 2018-10-17 AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1

Country Status (9)

Country Link
US (1) US11492624B2 (es)
EP (1) EP3697909A4 (es)
JP (2) JP7473472B2 (es)
CN (1) CN111212909A (es)
AU (1) AU2018352379A1 (es)
CA (1) CA3079413A1 (es)
TW (1) TW201918555A (es)
UY (1) UY37936A (es)
WO (1) WO2019079294A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116832169A (zh) * 2016-09-02 2023-10-03 箭头药业股份有限公司 靶向配体
CN116617390A (zh) * 2022-02-11 2023-08-22 武汉大学 Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用
CN117645995A (zh) * 2022-09-02 2024-03-05 北京福元医药股份有限公司 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
AU767195B2 (en) 1999-03-10 2003-11-06 Phogen Limited Delivery of substances to cells
US8137695B2 (en) 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
CN1300312C (zh) * 2004-08-23 2007-02-14 中国人民解放军军事医学科学院放射与辐射医学研究所 靶向去唾液酸糖蛋白受体的抗乙型肝炎病毒反义寡核苷酸的结构和用途
EP2087110A2 (en) * 2006-10-11 2009-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
EP3023495B1 (en) 2010-02-24 2019-05-08 Arrowhead Pharmaceuticals, Inc. Compositions for targeted delivery of sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
AU2012300476B2 (en) 2011-08-26 2016-03-24 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
CN103764153A (zh) 2012-04-18 2014-04-30 箭头研究公司 用于体内核酸递送的聚(丙烯酸酯)聚合物
JP2018535655A (ja) * 2015-09-29 2018-12-06 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
JOP20210043A1 (ar) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN109069529B (zh) 2016-03-07 2021-08-20 箭头药业股份有限公司 用于治疗性化合物的靶向配体
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
CN116832169A (zh) * 2016-09-02 2023-10-03 箭头药业股份有限公司 靶向配体

Also Published As

Publication number Publication date
EP3697909A1 (en) 2020-08-26
EP3697909A4 (en) 2021-10-13
WO2019079294A1 (en) 2019-04-25
CN111212909A (zh) 2020-05-29
JP7473472B2 (ja) 2024-04-23
TW201918555A (zh) 2019-05-16
CA3079413A1 (en) 2019-04-25
JP2024086876A (ja) 2024-06-28
JP2020537653A (ja) 2020-12-24
AU2018352379A1 (en) 2020-06-04
US11492624B2 (en) 2022-11-08
US20200283777A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
PH12019502333A1 (en) Targeted compositions
BR112018074185A2 (pt) 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas
CR20190294A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
PH12020550833A1 (en) Rnai constructs for inhibiting pnpla3 expression
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
MX2023012080A (es) Composiciones de acido ribonucleico interferente (arni) de transtiretina (ttr) y sus usos en el tratamiento o prevencion de enfermedades asociadas con transtiretina (ttr).
BR112018008746A2 (pt) composições e métodos para a inibição de atividade de arginase
CO2020015314A2 (es) Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
BR112017020895A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
NZ724277A (en) Compositions and methods for modulating pkk expression
PE20142362A1 (es) Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
PE20210921A1 (es) Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
UY37936A (es) AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1
CR20210371A (es) Constructos de arni para inhibir la expresión de pnpla3
GEP20217318B (en) Pyrazole magl inhibitors
MX2019002271A (es) Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso.
EP4219715A3 (en) Stabilized cebpa sarna compositions and methods of use
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
MX2021014465A (es) Construcciones de arni para inhibir la expresion de scap y metodos de uso de las mismas.
PH12020550244A1 (en) Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
WO2020104649A3 (en) Novel rna compositions and methods for inhibiting angptl8
WO2016103042A8 (en) Compositions and methods for inhibiting expression of adamts-5 and adam17

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201203